Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 3—March 2019
Research Letter

Rectal Lymphogranuloma Venereum, Buenos Aires, Argentina

Author affiliations: Hospital Fernández,. Buenos Aires, Argentina (L. Svidler López, B. Santos); Centro Privado de Cirugía y Coloproctología, Buenos Aires (L. La Rosa, D. Caffarena); Universidad de Buenos Aires, Buenos Aires (A.C. Entrocassi, M. Rodriquez Fermepin)

Cite This Article

Abstract

Among 34 men with proctitis in Buenos Aires, Argentina, 16 (47%) had Chlamydia trachomatis infection, 11 (68.8%) of which were biovar lymphogranuloma venereum. The outbreak was probably local, as in Europe. In Argentina, lymphogranuloma venereum should be a suspected cause of proctitis in HIV-infected men who have had unprotected anal sex with men.

Lymphogranuloma venereum (LGV) is a sexually transmitted infection caused by Chlamydia trachomatis serovars L1, L2, or L3 and their variants. LGV has been considered endemic to Asia, Africa, and the tropical region of South America. Over the past 2 decades, case reports of LGV in Argentina have been sporadic and regarding only patients who acquired the infection abroad.

In the Netherlands in 2003, an outbreak of rectal LGV among men who have sex with men (MSM), mainly HIV infected, was reported (1). This report was followed by many other reports from other developed countries (2,3).

LGV has been traditionally described as causing inflammation and swelling of the inguinal lymph nodes and also involving the rectum, causing acute proctitis, particularly among HIV-infected MSM (4). Since 2015, some clinicians in Argentina have suspected LGV in certain patients with proctitis (regardless of association with inflammatory tumors) in which C. trachomatis has been detected but not genotyped. Thus, we conducted a prospective study to assess the C. trachomatis genotypes as the causative agent of infectious proctitis in Buenos Aires, Argentina. Our study was conducted in a private practice and a public hospital, under a protocol previously approved by the hospital’s ethics committee (no. 201723).

From September 1, 2017, through February 1, 2018, we included in our study every man who visited either the private or public study site and who had rectal signs or symptoms of proctitis and had not taken antimicrobial drugs in the previous month. None of the included patients was referred by a previously included patient. Each participant signed an informed consent form.

Over the first 5 months, we obtained a rectal swab sample from 34 men on their first visit. To detect C. trachomatis, we extracted DNA from the samples by using real-time PCR targeting a cryptic plasmid fragment (Alert PCR; ELITech Molecular Diagnostics, https://www.elitechgroup.com). Positive samples were genotyped by ompA-based PCR restricted fragment length polymorphism (5).

Of the 34 samples analyzed, 16 were positive for C. trachomatis; 11 were identified as genotype L2 and 5 as genotypes D, F, or J. All participants reported having engaged in unprotected receptive anal sex in Argentina, except for 1 who had had receptive anal sex while in Mexico. None declared having traveled to an LGV-endemic area. Mean age was 31.63 years (range 22–43 years). All but 1 were HIV positive, and 5 had another sexually transmitted infection (1 had gonorrhea, 1 had syphilis and gonorrhea, 1 had syphilis only, and 2 had viral condylomas). The signs and symptoms of proctitis included rectal pain; tenesmus; and a discharge that was mucous, crystalline, hematic, or purulent. Endoscopic appearances of proctitis were variable, from mild to severe. Three patients had perianal lesions, 1 had a fistula, and 2 had ulcers. One patient had severe proctitis with rectal stenosis and was suspected of having had inflammatory bowel disease (IBD) for 1 year at the time of the first interview.

All patients were prescribed doxycycline for 3 weeks as recommended (4), resulting in complete resolution of proctitis and perianal ulcers. Two patients with chronic complications required additional treatments (surgical resolution of fistula and endoscopic dilatation of stenosis), resulting in complete resolution.

We observed a high prevalence (47%) of chlamydial infection within the studied group (16/34); the most frequent biovar was LGV (68.8% of the Chlamydia-infected patients). The cases included in this series were detected within a short period, which suggests a local outbreak. As in the series in Europe, the patients in Argentina were MSM, almost all HIV infected, who reported having had unprotected anal sex (6,7).

Signs and symptoms from most patients did not suggest LGV: 7 of the 11 with genotype L2 had mild or moderate proctitis similar to non-LGV infection. In 1 patient, severe proctitis mimicked an inflammatory tumor; in another, IBD. Proctitis is a nonspecific manifestation with diverse origins, for which clinical or endoscopic findings are insufficient to determine etiology, as observed in this case series. Also, because in about one quarter of patients with LGV infections the symptoms are mild or absent, diagnosis can be missed or late (8,9). Thus, given this evidence and the similarities between LGV and IBD, gastroenterologists should consider LGV as a differential diagnosis for patients with proctitis, especially HIV-infected MSM. Because the clinical assessment is not specific and quite inconclusive on which to base a diagnosis with certainty, genotyping is needed to indicate the proper patient care, management, and treatment. Including C. trachomatis typing as a routine diagnostic step also helps avoid chronic complications, stop the transmission chain (3,4,10), and provide useful information for epidemiologic surveillance. We conclude that in Buenos Aires, Argentina, as well as in countries in Europe, rectal LGV should be suspected as a cause of proctitis in HIV-infected MSM with a history of unprotected anal sex.

Dr. Svidler López is a surgeon who specializes in colon and rectum surgery in Buenos Aires, Argentina, and works at a public institution. She is also an associate professor at the School of Medicine of the University of Buenos Aires. Her main research interest is sexually transmitted infections.

Top

References

  1. Nieuwenhuis  RF, Ossewaarde  JM, Götz  HM, Dees  J, Thio  HB, Thomeer  MG, et al. Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis. 2004;39:9961003. DOIPubMedGoogle Scholar
  2. Rodríguez-Domínguez  M, Puerta  T, Menéndez  B, González-Alba  JM, Rodríguez  C, Hellín  T, et al. Clinical and epidemiological characterization of a lymphogranuloma venereum outbreak in Madrid, Spain: co-circulation of two variants. Clin Microbiol Infect. 2014;20:21925. DOIPubMedGoogle Scholar
  3. Pallawela  SN, Sullivan  AK, Macdonald  N, French  P, White  J, Dean  G, et al. Clinical predictors of rectal lymphogranuloma venereum infection: results from a multicentre case-control study in the U.K. Sex Transm Infect. 2014;90:26974. DOIPubMedGoogle Scholar
  4. de Vries  HJ, Zingoni  A, Kreuter  A, Moi  H, White  JA; European Branch of the International Union against Sexually Transmitted Infections; European Academy of Dermatology and Venereology; European Dermatology Forum; European Society of Clinical Microbiology and Infectious Diseases; Union of European Medical Specialists; European Centre for Disease Prevention and Control; European Office of the World Health Organisation. 2013 European guideline on the management of lymphogranuloma venereum. J Eur Acad Dermatol Venereol. 2015;29:16. DOIPubMedGoogle Scholar
  5. Lan  J, Walboomers  JM, Roosendaal  R, van Doornum  GJ, MacLaren  DM, Meijer  CJ, et al. Direct detection and genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol. 1993;31:10605.PubMedGoogle Scholar
  6. Foschi  C, Marangoni  A, D’Antuono  A, Nardini  P, Compri  M, Bellavista  S, et al. Prevalence and predictors of Lymphogranuloma venereum in a high risk population attending a STD outpatients clinic in Italy. BMC Res Notes. 2014;7:225. DOIPubMedGoogle Scholar
  7. Latini  A, Zaccarelli  M, Paglia  MG, Donà  MG, Giglio  A, Moretto  D, et al. Inguinal and anorectal Lymphogranuloma Venereum: a case series from a sexually transmitted disease center in Rome, Italy. BMC Infect Dis. 2017;17:386. DOIPubMedGoogle Scholar
  8. Saxon  C, Hughes  G, Ison  C; UK LGV Case-Finding Group. Asymptomatic lymphogranuloma venereum in men who have sex with men, United Kingdom. Emerg Infect Dis. 2016;22:1126. DOIPubMedGoogle Scholar
  9. Van der Bij  AK, Spaargaren  J, Morré  SA, Fennema  HS, Mindel  A, Coutinho  RA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin Infect Dis. 2006;42:18694. DOIPubMedGoogle Scholar
  10. Quint  KD, Bom  RJ, Quint  WG, Bruisten  SM, van der Loeff  MF, Morré  SA, et al. Anal infections with concomitant Chlamydia trachomatis genotypes among men who have sex with men in Amsterdam, the Netherlands. BMC Infect Dis. 2011;11:63. DOIPubMedGoogle Scholar

Top

Cite This Article

DOI: 10.3201/eid2503.180600

Original Publication Date: January 31, 2019

Table of Contents – Volume 25, Number 3—March 2019

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Laura Svidler López, Hospital General de Agudos Juan A Fernandez, Surgery, Cerviño 3556, Buenos Aires C1425, Argentina

Send To

10000 character(s) remaining.

Top

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external